ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy?

Shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shot up 65.4% during mid-day trading on Friday . The company traded as high as $0.2670 and last traded at $0.2652. 1,507,772 shares were traded during trading, an increase of 349% from the average session volume of 336,132 shares. The stock had previously closed at $0.1603.

ZyVersa Therapeutics Stock Performance

The firm has a market cap of $2.10 million, a price-to-earnings ratio of -0.20 and a beta of 0.81. The stock has a 50-day moving average of $0.14 and a 200-day moving average of $0.21.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.